News

Press Releases

Found 27 Results

July 28, 2025

OncoC4 Announces New Preclinical Data Highlighting ONC-841, a Novel SIGLEC 10 Antibody, as a Potential New Class of Therapeutics for Alzheimer’s Disease

SIGLEC 10 identified as a genetic driver for amyloid plaque formation in mice ONC-841 blockade reduced amyloid plaques, normalized microglia […]

July 22, 2025

OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US

Excellent safety observed across initial dose escalation with objective response at the lowest dose tested (1 mg/kg of AI-081) ROCKVILLE, […]

July 15, 2025

OncoC4 to Present at the 2025 Orphan Drug Summit on Strategies to Eliminate Anti-Drug Antibodies in Orphan Therapies

Multipronged approach to overcome the challenge of anti-drug antibodies to serve as the foundation of new subsidiary, AdaMunix ROCKVILLE, Maryland, […]

June 3, 2025

(UroToday.com) ASCO 2025: PRESERVE-006: Phase 1 Study of Gotistobart (BNT316/ONC-392) in Combination with Lutetium Lu 177 Vipivotide Tetraxetan in Patients with mCRPC

Full report from UroToday: https://www.urotoday.com/conference-highlights/asco-2025/asco-2025-prostate-cancer/160813-asco-2025-preserve-006-phase-1-study-of-gotistobart-bnt316-onc-392-in-combination-with-lutetium-lu-177-vipivotide-tetraxetan-in-patients-with-mcrpc.html

April 16, 2025

OncoC4 Selected to Present at the 2025 AACR Meeting’s Showcase Session

Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody Initial Phase 1 […]